Onco-hematology
Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.
1 Aug, 2022 | 11:46h | UTC
Commentary on Twitter
? Venetoclax plus gilteritinib yields modified composite complete response of 75% in FLT3-mutated relapsed/refractory #AcuteMyeloidLeukemia
Read in #JCO ➡️ https://t.co/L7wxJ63qv9 #AML #leusm @Daver_Leukemia @jaltmanmd pic.twitter.com/ksXw1DNMsE
— Journal of Clinical Oncology (@JCO_ASCO) July 29, 2022
RCT | Short vs. extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia.
27 Jul, 2022 | 12:17h | UTCShort versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary: Short-Course or Extended Antibiotics in Febrile Neutropenia? – Medscape (free registration required)
Commentary on Twitter
NEW online—Short-term is not inferior to extended carbapenem in patients with haematological malignancy and neutropenic fever of unknown origin, however, higher serious adverse events and mortality were noted in the short treatment group: the SHORT trial https://t.co/FOp1M3D6cL pic.twitter.com/6z5e8MSEgQ
— The Lancet Haematology (@TheLancetHaem) June 10, 2022
Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.
27 Jul, 2022 | 11:53h | UTCLong-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer
Commentaries:
CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay
RCT | Enasidenib vs. conventional care in mutant-IDH2 relapsed/refractory acute myeloid leukemia.
22 Jul, 2022 | 11:31h | UTC
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
20 Jul, 2022 | 12:08h | UTCThe epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends – The Lancet Haematology (free registration required)
Commentary on Twitter (thread – click for more)
@CUHKMedicine: collaborative work with @APRU1997 colleagues published. @TheLancet Haematology: Epidemiological Landscape of Multiple Myeloma from Cancer Registry Analysis @CUHKGlobal pic.twitter.com/17tr2Z30Xh
— Wong Chi Sang Martin (@drwong_martin) July 14, 2022
Single-arm phase 2 study | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
20 Jul, 2022 | 11:37h | UTCSafety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
ELN International Recommendations for the diagnosis and management of acute myeloid leukemia in adults.
19 Jul, 2022 | 13:28h | UTC
Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.
19 Jul, 2022 | 13:00h | UTCLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)
Related:
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Lisocabtagene maraleucel as second-line therapy in adults with R/R large B-cell #lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study https://t.co/NwkfPmVHu0 #lymsm pic.twitter.com/jHj5rFadV2
— The Lancet Oncology (@TheLancetOncol) July 13, 2022
RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
19 Jul, 2022 | 12:57h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)
RCT | Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin’s lymphoma.
18 Jul, 2022 | 11:13h | UTCOverall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma – Mayo Clinic
The EBMT nursing guidelines on CAR-T Therapy | A framework for patient care and managing common toxicities.
14 Jul, 2022 | 12:45h | UTC
Review | Cardiovascular disease in myeloproliferative neoplasms.
14 Jul, 2022 | 12:38h | UTC
Single-arm study | Long-term benefits of Tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm.
14 Jul, 2022 | 12:13h | UTCRelated Study: Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm – New England Journal of Medicine
RCT | Neutropenic versus regular diet for acute leukemia induction chemotherapy.
13 Jul, 2022 | 11:45h | UTCNeutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial – BMJ Supportive & Palliative Care (link to abstract – $ for full-text)
Related:
Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer – European Journal of Cancer (link to abstract – $ for full-text)
Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis – BMJ Supportive & Palliative Care (link to abstract – $ for full-text)
Things We Do For No Reason: Neutropenic Diet – Journal of Hospital Medicine (PDF)
RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
11 Jul, 2022 | 11:49h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.
8 Jul, 2022 | 11:53h | UTCRelated:
AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.
RCT | Efficacy and safety of a Pegasparaginase-based chemotherapy regimen vs. an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal Natural Killer/T-Cell Lymphoma.
8 Jul, 2022 | 11:21h | UTCEfficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Step Toward Improved Treatment of a Rare Virus-Associated Cancer – JAMA Oncology (free for a limited period)
See also: Visual Abstract
Cohort Study | Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma.
5 Jul, 2022 | 11:39h | UTCNews Release: Mantle cell lymphoma treatment varies according to setting – Weill Cornell Medicine
RCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.
4 Jul, 2022 | 12:21h | UTC[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck
— The Lancet Haematology (@TheLancetHaem) June 29, 2022
FDA warns about possible increased risk of death and serious side effects with duvelisib.
4 Jul, 2022 | 11:51h | UTC2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
Editorial | Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time?
4 Jul, 2022 | 11:48h | UTCOriginal Studies:
Single-arm phase II study: Venetoclax added to Cladribine plus low-dose Cytarabine alternating with 5-Azacitidine in older patients with newly diagnosed acute myeloid leukemia.
30 Jun, 2022 | 10:14h | UTCPhase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia – Journal of Clinical Oncology (link to abstract – $ for full-text)
Cohort Study: Burden of long-term morbidity borne by survivors of acute myeloid leukemia treated with blood or marrow transplantation.
29 Jun, 2022 | 10:56h | UTC
Commentary on Twitter
We must understand life after BMT better, what it MEANS for a patient surviving intensive but curative treatment. Kudos to this @JCO_ASCO paper but we need better designs: versus other treatments, in BMT cohorts!
Life's gray, not categorical…#bmtsmhttps://t.co/E4YQV4LzoN pic.twitter.com/P7bMWXMTB5— Nico Gagelmann (@NicoGagelmann) June 23, 2022
Under a https://creativecommons.org/licenses/by-nc-nd/4.0/ license
Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.
29 Jun, 2022 | 10:50h | UTC